Assoc Dir Maj Gfts, DC Area

first_imgJob DescriptionThe Associate Director of Major Gifts, Greater Washington, DC MetroArea will solicit philanthropic gifts from alumni, parents, andfriends, which align with the overall university strategicpriorities. This highly motivated professional will be involvedwith the planning and implementation of major gift fundraisingefforts in support of current operations, endowment, capital, andother priorities from private sources in support of operations inthe Washington, DC region. This position will fulfill the dutiesunder the direction of the Associate Vice President forAdvancement, Greater Washington, DC Metro Area. The AssociateDirector of Major Gifts will:Assist with fundraising activities in the greater Washington, DCmetro area within designated time frames.Have a portfolio of between 100-125 prospects.Have typical solicitation ranges of $100,000 to $1,000,000.Close $1,000,000 per year using a three-year rolling average.Close on average 10-13 gifts per fiscal year.Develop and implement cultivation and solicitation strategies whichinclude building, managing, and soliciting a portfolio of majorgift prospects.Establish strong working relationships with other advancement,collegiate and constituent development officers and staff to fostera productive work environment.Required QualificationsBachelor’s degree and significant experience or a Master’s degree.Demonstrated experience in fundraising, sales/marketing,advertising, public relations, communications or a related field.Willingness to travel on a frequent basis. Individuals shoulddemonstrate professionalism, with strong communication skills andbe capable of motivating volunteers as well as donors. Thesuccessful candidate will be self-motivated and have the ability towork as a team member in a complex organization.Preferred QualificationsDemonstrated successful track record in fundraising. Preferencegiven to candidates with experience in higher educationfundraising. Preference for proven success in building productiverelationships with senior administrators, key business leaders,faculty, staff, institutional boards, volunteers, and/ordonors.Pay BandN/AAppointment TypeRegularSalary InformationCommensurate with ExperienceReview DateMarch 29,2021Additional InformationThe successful Candidate will be required to have a criminalconviction checkAbout Virginia TechDedicated to its motto, Ut Prosim (That I May Serve),Virginia Tech pushes the boundaries of knowledge by taking ahands-on, transdisciplinary approach to preparing scholars to beleaders and problem-solvers. A comprehensive land-grant institutionthat enhances the quality of life in Virginia and throughout theworld, Virginia Tech is an inclusive community dedicatedto knowledge, discovery, and creativity. The university offers morethan 280 majors to a diverse enrollment of more than 36,000undergraduate, graduate, and professional students in eightundergraduatecolleges , a school ofmedicine , a veterinarymedicine college, Graduate School , and Honors College . The universityhas a significant presence across Virginia, including the Innovation Campusin Northern Virginia; the Health Sciences and Technology Campus inRoanoke; sites in Newport News and Richmond; and numerous Extension offices andresearchcenters . A leading global research institution, Virginia Techconducts more than $500 million in research annually.Virginia Tech does not discriminate against employees, students, orapplicants on the basis of age, color, disability, sex (includingpregnancy), gender, gender identity, gender expression, geneticinformation, national origin, political affiliation, race,religion, sexual orientation, or veteran status, or otherwisediscriminate against employees or applicants who inquire about,discuss, or disclose their compensation or the compensation ofother employees or applicants, or on any other basis protected bylaw.If you are an individual with a disability and desire anaccommodation, please contact Brandi Barnett at [email protected] during regular businesshours at least 10 business days prior to the event.Advertised: March 2, 2021Applications close:last_img read more

Read More →

Manhattan’s luxury market streak continues for 8th week

first_img Full Name* Message* From left: 998 Fifth Avenue, One57 and Extell’s Gary Barnett (Photos via Beyond My Ken and Godsfriendchuck/Wikimedia)An Upper East Side co-op and a sponsor unit at Extell Development’s One57 were among the priciest contracts signed last week, as Manhattan’s luxury market closed two straight months of elevated activity.Last week there were 47 contracts signed, up from 41 the week prior, according to Olshan Realty’s weekly report on contracts for Manhattan properties asking $4 million or more.It was the eighth consecutive week in which more than 30 contracts were signed. It’s the longest such streak since Olshan began tracking Manhattan’s luxury market in 2006.Read moreManhattan’s luxury market continues 7-week contract streakFormer Goldman exec behind Epstein townhouse buy: reportVince Viola’s UES mansion was Manhattan’s priciest deal last week Email Address* Donna Olshan, author of the report, said the streak is largely being driven by the “New York metro area buyer” and said she would expect the volume of contracts to taper off as the summer approaches. She noted that could change if international travel restarts.“We’re only operating with one arm,” she said. “But the streak could be sustained if the market opened up to the global audience.”The average discount from initial ask to final for the 41 contracts dropped to 8 percent, down from 11 percent the week before. The median price was $5.94 million and the homes spent an average of 598 days on the market. Of the deals, there were 32 condos, 12 co-ops and three townhouses.The most expensive contract was for a four-bedroom co-op at 998 Fifth Avenue. The sprawling apartment with a 38-foot living room and 33-foot master bedroom faces Central Park and the Metropolitan Museum of Art. It was listed for $29.5 million in November 2018 and was last asking $24 million.The second priciest deal was for a three-bedroom condo at Extell Development’s One57 tower. Unit 66B was initially seeking $28.5 million when the developer launched sales in 2013. It went into contract asking $20.9 million. The 4,193-square-foot unit has views of Central Park.Contact Erin Hudsonlast_img read more

Read More →

Sensational news for Pironkova!

first_imgThe most successful Bulgarian tennis player in the last decade, Tsvetana Pirovkova, will return to the big sport. It is on the list for the main scheme starting on August 31 at the US Open, informs BTA.The 32-year-old from Plovdiv, former number 31 in the world, has not played at Wimbledon since the summer of 2017, where she lost to Caroline Wozniacki. She then treated an injury and then gave birth. Therefore, you can take advantage of the so-called. “protective ranking” – the place she occupied before going out on maternity leave. And that’s №123 in the WTA rankings.Winbet – victory is an emotion! (18+)This position will probably guarantee her a place in the main draw of the tournament. On March 11 this year, the 32-year-old Pironkova announced that she was returning to tennis after the birth of her son Alexander.The woman from Plovdiv, who played in the semifinals of Wimbledon in 2010 and the quarterfinals of Roland Garros in 2016, reached the quarterfinals of the US Open in 2012. She last participated in the US Open in 2016. when in the second round he lost to Johanna Conte.last_img read more

Read More →

Mylan boosts EpiPen patient programs, doesn’t budge on price

first_imgMylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has climbed more than 600 percent over the past decade.But the drugmaker didn’t budge on its price, which has drawn ire both in Congress and from families that have had to shell out increasingly large sums for the potentially life-saving treatment.That means the insurers and employers that pay the bulk of the EpiPen cost for many patients will continue to do so, contributing to higher health insurance costs.FILE – This Oct. 10, 2013, file photo, shows an EpiPen epinephrine auto-injector, a Mylan product, in Hendersonville, Texas. Mylan, now in the crosshairs over severe price hikes for its EpiPen, said Thursday, Aug. 25, 2016, it will expand programs that lower out-of-pocket costs by as much as half. (AP Photo/Mark Zaleski, File)“That’s just going to come out in the premiums,” said Sabrina Corlette, a research professor at the Georgetown University’s Health Policy Institute. “Everybody suffers, except the Mylan investors.”The average price of a two-dose EpiPen package climbed to about $608 earlier this year, up from around $94 nine years ago, according to the Elsevier Clinical Solutions’ Gold Standard Drug Database.Mylan CEO Heather Bresch told CNBC Thursday that lowering the price was not an option.“Had we reduced the list price, I couldn’t ensure that everyone who needs an EpiPen gets one,” she said.EpiPens are used in emergencies to treat severe allergies that can lead to anaphylactic shock. Roughly 40 million Americans have severe allergies to spider bites, bee stings and foods like nuts, eggs and shellfish.Democratic presidential candidate Hillary Clinton and members of Congress from both parties have quickly ramped up criticism of the company and its pricing.Pharmaceutical and biotech industries can fuel American innovation, and combat debilitating diseases, Clinton said Wednesday. But she added that “it’s wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them.”Bresch said Thursday that Mylan gets $274 for a two-dose EpiPen package. The rest of the $608 price goes to entities that stand between the drugmaker and the patient, like insurers, pharmacy benefits managers, wholesalers and drugstores.“This isn’t an EpiPen issue,” she said. “This isn’t a Mylan issue. This is a health care issue.”However, it is Mylan that is increasing the price of the drug and the company stuck by those price hikes Thursday.That stance brought a wave of new money from investors who drove Mylan’s shares up more than 3 percent in early trading, while all major U.S. indexes were in decline.Mylan did say, however, that it was doubling the eligibility for its patient assistance program to people with incomes four times higher than the federal poverty level. It said that means a family of four making up to $97,200 would pay nothing out of pocket for the treatment. It also noted that its $300 savings card would cut the bill in half for patients who would otherwise have to pay full price for the EpiPen.Patients also will be able to order the injected medicine directly from the company, to help lower costs.These measures could provide significant help for people with no coverage facing the full bill. But they might have more limited value to a patient whose insurer will cover most of the bill anyway and whose future premium could be affected each year.Customers of Express Scripts Holding Co., the nation’s largest pharmacy benefits manager, pay about $73.50 out of pocket for an EpiPen prescription, spokesman Brian Henry said. He noted that price has stayed relatively stable the past couple years.Last year, more than 3.6 million U.S. prescriptions for two-packs of EpiPens were filled, according to data firm IMS Health. That brought in sales of nearly $1.7 billion for Mylan.AP Business Writer Joseph Pisani in New York also contributed to this story.last_img read more

Read More →